Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

Clara E Negri; Sarah S Gonçalves; Ana Cristina P Sousa; Maria Daniela Bergamasco; Marinês D V Martino; Flavio Queiroz-Telles; Valerio Rodrigues Aquino; Paulo de Tarso O Castro; Ferry Hagen; Jacques F Meis; Arnaldo L Colombo

doi:10.1128/AAC.00608-17

Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

Clara E Negri
, Sarah S Gonçalves
, Ana Cristina P Sousa
, Maria Daniela Bergamasco
, Marinês D V Martino
, Flavio Queiroz-Telles
, Valerio Rodrigues Aquino
, Paulo de Tarso O Castro
, Ferry Hagen
, Jacques F Meis
, Arnaldo L Colombo^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.

Original language	English
Article number	e00608-17
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	11
DOIs	https://doi.org/10.1128/AAC.00608-17
Publication status	Published - Nov 2017
Externally published	Yes

Keywords

Antifungal Agents/therapeutic use
Aspergillosis/drug therapy
Aspergillus fumigatus/drug effects
Brazil
Drug Resistance, Fungal/genetics
Humans
Invasive Fungal Infections/drug therapy
Itraconazole/therapeutic use
Microbial Sensitivity Tests
Retrospective Studies
Voriconazole/therapeutic use

Access to Document

10.1128/AAC.00608-17

Cite this

Negri, C. E., Gonçalves, S. S., Sousa, A. C. P., Bergamasco, M. D., Martino, M. D. V., Queiroz-Telles, F., Aquino, V. R., Castro, P. D. T. O., Hagen, F., Meis, J. F., & Colombo, A. L. (2017). Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients. Antimicrobial Agents and Chemotherapy, 61(11), Article e00608-17. https://doi.org/10.1128/AAC.00608-17

@article{46c7d6f449e34e078d9e72abe8fc460a,

title = "Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients",

abstract = "Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8\%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.",

keywords = "Antifungal Agents/therapeutic use, Aspergillosis/drug therapy, Aspergillus fumigatus/drug effects, Brazil, Drug Resistance, Fungal/genetics, Humans, Invasive Fungal Infections/drug therapy, Itraconazole/therapeutic use, Microbial Sensitivity Tests, Retrospective Studies, Voriconazole/therapeutic use",

author = "Negri, \{Clara E\} and Gon{\c c}alves, \{Sarah S\} and Sousa, \{Ana Cristina P\} and Bergamasco, \{Maria Daniela\} and Martino, \{Marin{\^e}s D V\} and Flavio Queiroz-Telles and Aquino, \{Valerio Rodrigues\} and Castro, \{Paulo de Tarso O\} and Ferry Hagen and Meis, \{Jacques F\} and Colombo, \{Arnaldo L\}",

year = "2017",

month = nov,

doi = "10.1128/AAC.00608-17",

language = "English",

volume = "61",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "11",

}

Negri, CE, Gonçalves, SS, Sousa, ACP, Bergamasco, MD, Martino, MDV, Queiroz-Telles, F, Aquino, VR, Castro, PDTO, Hagen, F, Meis, JF & Colombo, AL 2017, 'Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients', Antimicrobial Agents and Chemotherapy, vol. 61, no. 11, e00608-17. https://doi.org/10.1128/AAC.00608-17

TY - JOUR

T1 - Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

AU - Negri, Clara E

AU - Gonçalves, Sarah S

AU - Sousa, Ana Cristina P

AU - Bergamasco, Maria Daniela

AU - Martino, Marinês D V

AU - Queiroz-Telles, Flavio

AU - Aquino, Valerio Rodrigues

AU - Castro, Paulo de Tarso O

AU - Hagen, Ferry

AU - Meis, Jacques F

AU - Colombo, Arnaldo L

PY - 2017/11

Y1 - 2017/11

N2 - Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.

AB - Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil.

KW - Antifungal Agents/therapeutic use

KW - Aspergillosis/drug therapy

KW - Aspergillus fumigatus/drug effects

KW - Brazil

KW - Drug Resistance, Fungal/genetics

KW - Humans

KW - Invasive Fungal Infections/drug therapy

KW - Itraconazole/therapeutic use

KW - Microbial Sensitivity Tests

KW - Retrospective Studies

KW - Voriconazole/therapeutic use

U2 - 10.1128/AAC.00608-17

DO - 10.1128/AAC.00608-17

M3 - Article

C2 - 28893772

SN - 0066-4804

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 11

M1 - e00608-17

ER -

Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this